The prognostic value of CD2, CD4, and HLA-DR expression and FLT3-ITD mutation in adult acute promyelocytic leukemia

References

• Shigeto S, Matsuda K, Yamaguchi A, et al. Rapid diagnosis of acute promyelocytic leukemia with the PML-RARA fusion gene using a combination of droplet-reverse transcription-polymerase chain reaction and instant-quality fluorescence in situ hybridization. Clin Chim Acta. 2016;453:38–41.
   PubMed Web of Science ®Google Scholar
• De Braekeleer E, Douet-Guilbert N, De Braekeleer M. RARA fusion genes in acute promyelocytic leukemia: a review. Expert Rev Hematol. 2014;7(3):347–357.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–2515.
   PubMed Web of Science ®Google Scholar
• Ades L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010;115(9):1690–1696.
   PubMed Web of Science ®Google Scholar
• Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248–1254.
   PubMed Web of Science ®Google Scholar
• McCulloch D, Brown C, Iland H. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. Onco Targets Ther. 2017;10:1585–1601.
   PubMed Web of Science ®Google Scholar
• Mi JQ, Li JM, Shen ZX, et al. How to manage acute promyelocytic leukemia. Leukemia. 2012;26(8):1743–1751.
   PubMed Web of Science ®Google Scholar
• Ono T, Takeshita A, Kishimoto Y, et al. Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. Cancer Sci. 2014;105(1):97–104.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775–783.
   PubMed Web of Science ®Google Scholar
• Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol. 2016;95(5):673–680.
   PubMed Web of Science ®Google Scholar
• Takenokuchi M, Kawano S, Nakamachi Y, et al. FLT3/ITD associated with an immature immunophenotype in PML-RARalpha leukemia. Hematol Rep. 2012;4(4):e22.
   PubMedGoogle Scholar
• Zeng H, Yin LD, Li P, et al. The level of peripheral blood circulating CD34+ cells is higher in acute promyelocytic leukemia patients with adverse prognostic factors. Hematology. 2016;21(9):513–519.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.
   PubMed Web of Science ®Google Scholar
• Shen ZX, Huang XJ, Ma J, et al. Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2018). Chin J Hematol. 2018;39(3):179–183.
   Google Scholar
• Stepanova K, Sinkora M. Porcine γδ T lymphocytes can be categorized into two functionally and developmentally distinct subsets according to expression of CD2 and level of TCR. J Immunol. 2013;190(5):2111–2120.
   PubMed Web of Science ®Google Scholar
• Kaito K, Katayama T, Masuoka H, et al. CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis. Clin Lab Haematol. 2005;27(5):307–311.
   PubMedGoogle Scholar
• Xu F, Yin CX, Wang CL, et al. Immunophenotypes and immune markers associated with acute promyelocytic leukemia prognosis. Dis Markers. 2014;2014:421906.
   PubMed Web of Science ®Google Scholar
• Miwa H, Mizutani M, Mahmud N, et al. Biphasic expression of CD4 in acute myelocytic leukemia (AML) cells: AML of monocyte origin and hematopoietic precursor cell origin. Leukemia. 1998;12(1):44–51.
   PubMed Web of Science ®Google Scholar
• Albano F, Mestice A, Pannunzio A, et al. The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. Haematologica. 2006;91(3):311–316.
   PubMed Web of Science ®Google Scholar
• Lukaszewicz AC, Faivre V, Payen D. Is monocyte HLA-DR expression monitoring a useful tool to predict the risk of secondary infection. Minerva Anestesiol. 2010;76(9):737–743.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Rayon C, Vellenga E, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 2011;117(6):1799–1805.
   PubMed Web of Science ®Google Scholar
• Beitinjaneh A, Jang S, Roukoz H, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 2010;34(7):831–836.
   PubMed Web of Science ®Google Scholar
• Lucena-Araujo AR, Kim HT, Jacomo RH, et al. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol. 2014;93(12):2001–2010.
   PubMed Web of Science ®Google Scholar
• Kutny MA, Moser BK, Lauman K, et al. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59(4):662–667.
   PubMed Web of Science ®Google Scholar